Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

Published:2014-07-29 Issue:9 Volume:4 Page:1036-1045
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Janjigian Yelena Y.,Smit Egbert F.,Groen Harry J.M.,Horn Leora,Gettinger Scott,Camidge D. Ross,Riely Gregory J.,Wang Bushi,Fu Yali,Chand Vikram K.,Miller Vincent A.,Pao William

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 337 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants;Nature Communications;2024-03-28

2. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study;Journal for ImmunoTherapy of Cancer;2024-03

3. The Efficient Activity of Glabridin and its Derivatives Against EGFRmediated Inhibition of Breast Cancer;Current Medicinal Chemistry;2024-02

4. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

5. A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments;Cancer Treatment Reviews;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP